Comparison of the effect of calcium gluconate and batroxobin on the release of transforming growth factor beta 1 in canine platelet concentrates by Raul F Silva et al.
Silva et al. BMC Veterinary Research 2012, 8:121
http://www.biomedcentral.com/1746-6148/8/121RESEARCH ARTICLE Open AccessComparison of the effect of calcium gluconate
and batroxobin on the release of transforming
growth factor beta 1 in canine platelet
concentrates
Raul F Silva1,2*, Jorge U Carmona2 and Cleuza MF Rezende1Abstract
Background: The clinical use of autologous platelet concentrates (also known as platelet-rich plasma) on the field
of regenerative therapy, in the last decade has been the subject of several studies especially in equine medicine
and surgery. The objectives of this study was: 1) to describe and compare the cellular population in whole blood,
lower fraction (A) and upper fraction (B) of platelet concentrates, 2) to measure and compare the transforming
growth factor beta 1 (TGF-β1) concentration in plasma and both platelet concentrates after be activated with
calcium gluconate or batroxobin plus calcium gluconate and, 3) to determine correlations between cell counts in
platelet concentrates and concentrations of TGF-β1. Blood samples were taken from 16 dogs for complete blood
count, plasma collection and platelet concentrates preparation. The platelet concentrates (PC) were arbitrarily
divided into two fractions, specifically, PC-A (lower fraction) and PC-B (upper fraction). The Platelet concentrates
were analyzed by hemogram. After activated with calcium gluconate or batroxobin plus calcium gluconate, TGF-β1
concentration was determined in supernatants of platelet concentrates and plasma.
Results: There were differences statistically significant (P< 0.05) for the platelet count and leukocyte count and
TGF-β1 concentration between whole blood, plasma and both platelet concentrates. A significant correlation was
found between the number of platelets in both platelet concentrates and TGF-β1 concentration. Platelet collection
efficiency was 46.34% and 28.16% for PC-A and PC-B, respectively. TGF-β1 concentration efficiency for PC activated
with calcium gluconate was 47.75% and 31.77%, for PC-A and PC-B, respectively. PC activated with batroxobin plus
CG showed 46.87% and 32.24% for PC-A and PC-B, respectively.
Conclusions: The methodology used in this study allows the concentration of a number of platelets and TGF-β1
that might be acceptable for a biological effect for clinical or experimental use as a regenerative therapy in dogs.
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The healing process is directed by complex biological
mechanisms that involve many cells and proteins, such
as cytokines and growth factors (GF), among others.
Cellular and molecular interactions allow, under physio-
logical conditions, the repair or regeneration of damaged
tissues [1,2]. Platelets play a central role in the healing* Correspondence: raul.silva@ucaldas.edu.co
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reproduction in any medium, provided the orprocess. These cytoplasmic fragments not only have
hemostatic properties [3], but also have pro-inflammatory,
regulatory [4] and regenerative properties, which are
mediated by interaction with other cells (neutrophils
and endothelial cells), GF, chemokines and other regula-
tory molecules [5].
Currently, there is a growing interest in the use of au-
tologous platelet concentrates (PC), also known as plate-
let rich plasma (PRP) for stimulating the healing process
and promoting regeneration instead of reparation. Plate-
let alpha granules [4,6] contain at least seven GF directlyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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forming growth factor beta isoform 1 (TGF-β1) is of
pivotal importance for its actions on cell proliferation,
angiogenesis and extracellular matrix deposition [7].
Many substances could potentially be used for platelet
activation as a previous step for the clinical use PC.
Platelet activation understood as a combination of fi-
brinogen cleavage leading to fibrin mesh formation and
externalization of alpha granules containing growth fac-
tors [8]. Arbitrarily, activating substances could are clas-
sified according to their chemical structure in proteic,
non-proteic forms and combination of both. Proteic ac-
tivating substances include thrombin (either from bovine
or autogenous sources) [9,10], and soluble collagen type
I [11] amongst others. Calcium salts, such as calcium
chloride and calcium gluconate [9] are classified as non-
proteic activating substances. Combination of both in-
cludes batroxobin plus calcium gluconate [10].
Some protocols for platelet activation include the use
of a calcium salt solely and others include the combin-
ation of a calcium salt plus a proteic activating sub-
stance. To date, there is no convincing data about what
is the best activating substance (in terms of GF concen-
tration) for PC activation and more research is necessary
to know the effect of these substances (either alone or
combined) on the release of platelet main derived GF,
such as TGF-β1.
There is information on basic biological aspects and
clinical use of PC in musculoskeletal and soft tissue in-
juries in human beings [12-15] and horses [16-18]. The
study presented here provides the description of a man-
ual protocol for producing two kinds of canine PC ar-
bitrarily classified as lower fraction (PC-A) and upper
fraction (PC-B) and evaluates the effect of a non-proteic
activating substance (calcium gluconate -CG-) and theTable 1 General results of the cellular variables. Data present
Variable
Whole Blood
PLT × 103/μL 330.75 (18.28) a
PCV % 45.50 (1.05) a
WBC× 103/μL 10.94 (0.77) a
LYM× 103/μL 2.27 (0.25) a
LYM % 20.97 (2.08) a
MID× 103/μL 0.49 (007) a
MID % 4.49 (0.55) a
GRA× 103/μL 8.20 (0.68) a
GRA % 74.54 (2.01) a
MPV (fL) 8.36 (0.18) a
PDW % 35.53 (0.47) a
Statistically significant differences by SNK test. a,b,c Different letters represent significombination of a proteic activating substance (batroxo-
bin) plus CG on the release of TGF-β1 from canine PC.
The aims of this study were: 1) to describe and com-
pare the cellular population in whole blood, lower frac-
tion (A) and upper fraction (B) of platelet concentrates
(PC), 2) to measure and compare the of TGF-β1 concen-
tration plasma in both PC after be activated with cal-
cium gluconate (CG) or batroxobin plus CG and, 3) to




Platelet, WBC, and GRA counts were significantly differ-
ent (P< 0.01) between whole blood and both PC. PC-A
showed the highest PLT and WBC counts. GRA concen-
tration was highest in whole blood. The absolute count
of LYM was significantly lower (P< 0.01) in whole blood
and PC-B in comparison with PC-A. However, the rela-
tive count of LYM was significantly lower (P< 0.01) in
whole blood in comparison with both PC. Absolute and
relative counts of MID were similar for each blood
component. MPV was significantly higher (P< 0.01) in
PC-A, in comparison with whole blood and PC-B.
PDW was significantly different between each blood
component (Table 1).
Total protein concentration
Total protein (mg/mL) concentration was similar for
each blood component (Table 2).
Transforming growth factor beta 1 concentration
Independently of the activating substance used, the
TGF-β1 concentrations (ng/mL or ng/mg total protein)
were significantly different (P< 0.01) between plasmaed as mean (standard error)
Blood component
Platelet Concentrate-A Platelet Concentrate-B
1072.90 (84.01)b 652.00 (56.47)c
5.81 (1.01) a 1.58 (0.84) c
17.86 (2.56) b 4.46 (1.27) c
11.38 (1.63) b 3.44 (1.26) a
65.78 (3.41) b 67.18 (6.82) b
0.61 (0.21) a 0.23 (0.10) a
3.08 (0.79) a 3.60 (0.93) a
5.85 (1.11) b 0.77 (0.22) c
31.14 (3.60) b 29.22 (2.38) c
8.80 (0.17) b 8.31 (0.13) a
36.79 (0.37) b 35.45 (0.45) a
cant (P< 0.01).
Table 2 Concentration of transforming growth factor beta 1 in plasma and supernatants of platelet concentrates (PC).




Calcium Gluconate TGF-β1 (ng/mL) 13.7 (2.88) a 45.8 (5.43) b 30.5 (3.11) c
TP (mg/mL) 62.0 (0.96) a 62.3 (0.79) a 62.6 (1.06) a
TGF-β1 (ng/mg of TP) 0.22 (0.05) a 0.73 (0.09) b 0.49 (0.05) c
Batroxobin plus calcium gluconate TGF-β1 (ng/mL) 13.7 (2.88) a 44.9 (5.65) b 30.9 (3.20) c
TP (mg/mL) 62.0 (0.96) a 63.1 (1.25) a 64.7 (1.65) a
TGF-β1 (ng/mg of TP) 0.22 (0.05) a 0.72 (0.09) b 0.48 (0.05) c
Statistically significant differences by SNK test. a,b,c Different letters represent significant (P< 0.01).
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found in PC-A. No differences were noted between the
two activating substances on the release of TGF-β1 of
both PC (Table 2).
Correlations
Highly significant correlations were found for PLT count
and TGF-β1 concentration in both PC, independently of
the activating substance used. For platelet concentrates
activated with CG the correlation coefficients were ρ=0.7
(P< 0.01) and ρ= 0.75 (P< 0.01) for PC-A and PC-B, re-
spectively. For platelet concentrates activated with batroxo-
bin plus CG the correlation coefficients were ρ= 0.71
(P< 0.01) and ρ= 0.75 (P< 0.01) for PC-A and PC-B,
respectively.
Collection (concentration) efficiency
Platelet collection efficiency was 46.34% and 28.16% for
PC-A and PC-B, respectively. The combined collection
efficiency for both PC was 74.5%. Platelet concentration
was 224.38% for PC-A and 97.13% for PC-B in compari-
son with platelet counts in whole blood. Data of TGF-β1
concentration efficiency for each PC after activation with
CG and batroxobin plus CG is presented in Table 3.
Discussion
This research describes a reliable method for producing
platelet concentrates and consequently for concentrating
GF, such as TGF-β1 from canine blood. Some manual
(tube) protocols [19-22] and a semi-automated method
[23] have been described for producing PC in dogs.Table 3 Concentration efficiency of transforming growth
factor beta 1 in supernatants of platelet concentrates (PC)
Activating substance Variable
Blood component
PC-A PC -B PC-A+B
Calcium gluconate TGF-β1 (%) 47.8 31.8 165.57
Batroxobin plus calcium gluconate TGF-β1 (%) 46.9 32.2 158.22Manual protocols were performed with either sodium
citrate [19-21] or ACD-A [22] as anticoagulant. Those
protocols included simple and double centrifugation
steps for concentrating between 400 X 103 to 1300 X
103 PLT/μL. However, platelets were counted manually
(light microscopy) and did not report additional hema-
tologic features of the resulting PC.
Platelet concentration reached in the protocol de-
scribed here was slightly lower than a semi-automated
double centrifugation method evaluated in dogs, which
presented a median concentration of 1336 PLT X 103/μL
[23]. However, this method is limited because it could
only be used in medium at large breed dogs, since it
requires 60 mL of blood for PC preparation. The proto-
col described here presents the advantage that PC is eas-
ily obtained by using one centrifugation step with a
small volume of blood. This last situation is important
when pediatric patients or small breed dogs are treated.
The size and weight of the blood cells, the relative
centrifugation forces (g) and time are factors that deter-
mine the cellular and molecular characteristics of a PC.
This concept is necessary for comparing the results of
the research described here with other published studies
in human beings [12-15] and horses [16-18]. The proto-
col described here permitted obtaining two kinds of dif-
ferent PC. Platelet concentrate-A presented a higher
concentration of PLT/μL, WBC/μL and TGF-β1/mL (in-
dependently of the activating substance used) in com-
parison with PC-B. From a comparative point of view
both canine and human blood present the same trend
when centrifuged for PC preparation. However, equine
blood requires a double centrifugation [24] for obtaining
a PC with an acceptable quantity of PLT.
There are a lot of controversies about the ideal num-
ber of concentrated platelets in a PC for its clinical use
in human beings and horses. Some researches consider
the highest number of platelets concentrated in PRP to
yield the best clinical results. This assumption could
emerge from experimental results observed in rabbits
where higher platelet concentrations were better for
osteointegration, than lower platelet concentration [25].
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in human beings [26] and horses [16] using PC with
300–400 X 103 PLT/μL.
Another fact that generates controversy is the presence
of leukocytes in PC. Some researches consider that WBC
are a contaminant of PRP and possibly deleterious for
tissues when treated, especially at high concentrations.
However, others believe that WBC are important regula-
tory cells contained in PRP and necessary for wound
healing [27]. To date, there are no studies that defini-
tively elucidate the significance of leukocytes in PRP.
However, when manual methods are used for producing
PC in human beings and horses, leukocyte concen-
trations are comparatively lower when semi-automated
methods are used. Unfortunately, there is no data about
WBC concentration in canine PC obtained by manual or
semi-automated methods. However, it is important to
note that platelet concentration of the protocol de-
scribed here was not correlated with WBC concentra-
tion. This situation is different for PC derived from
equine blood [24].
Both PC obtained in this study permitted concentrate
two (PC-B) and three (PC-A) fold the concentration of
TGF-β1 respect to the basal concentration of this protein
in plasma. These findings suggest that plasma platelets
were scarcely activated at the moment of blood extrac-
tion, since the MPV remained lower in whole blood in
comparison with the same parameter in PC-A. However,
although MPV value was statistically higher in PC-A in
comparison with PC-B and whole blood, this platelet
activation parameter remained between normal range
values for canine platelets [28]. Maybe, the reason, which
MPV was higher in PC-A, is related to the large number
of concentrated PLT and WBC. A single centrifugation
process produces cellular friction that could be most ac-
tive toward the platelet fraction near to the erythrocyte
package. This situation has also been observed in equine
PC obtained by simple and double centrifugation tube
methods [24].
Plasma TGF-β1 concentrations of this study were quite
similar to the values described for this protein from
serum of two dogs (16.5 and 19.9 ng/mL) [29]. However,
other research described plasma TGF-β1 concentration
ranging from 0.193-0.598 ng/mL. That study included
29 canine blood samples collected with EDTA by using a
double centrifugation protocol [30]. Plasma or serum
TGF-β1 concentrations described in these two last stud-
ies [29,30] could be influenced by methodological as-
pects such as the use or not of anticoagulant and the
type of antibody used for TGF-β1 measurement. To note,
this protein was measured in the present study with a
specific canine antibody for TGF-β1, whereas the studies
mentioned [29,30] used a human TGF-β1 antibody. How-
ever, this is only an assumption and further studies arenecessary to validate the actual utility of human or ca-
nine ELISA kits for canine TGF-β1 measurement.
Plasma and both PC of this study presented higher
concentrations of TGF-β1 in comparison with the results
of the same protein from autologous conditioned plasma
(ACP) and plasma obtained with ACD-A from blood of
dogs [31]. In that research [31], a TGF-β1 mean concen-
tration of 1.24 ± 0.59 ng/mL was obtained from ACP
with PLT counts ranging from 277–293.5 X 103/μL. How-
ever, the ELISA human kit used did not detect plasma
TGF-β1 concentration. In addition, no statistical correl-
ation was found between the number of PLT concen-
trated and the TGF-β1 concentrations [31]. This last result
was different from the findings of the study described
here; since strong correlations (70%) were noticed be-
tween PLT counts and TGF-β1 concentration. The differ-
ence between the results obtained in that study [31] and
the findings of the research presented here could be
related to the specificity of the antibody used for TGF-β1
detection and because they used no activating sub-
stances for stimulating the release of growth factors
from platelets.
There is some controversy about the need of adding
activating substances to induce the release of GF con-
tained in PLT. Some researchers think that activating
substances are not necessary when PC will be used as an
injection for the treatment of tendon and ligament le-
sions or arthropaties [32]. They argue that connective
tissues are rich in collagen and that this autologous pro-
tein is enough to induce platelet activation. Other re-
searchers believe that the use of activating substances is
necessary to stimulate the massive release of growth fac-
tors in the foci of the lesion and thus increasing the
healing process of the affected tissue [32]. However, to
date there is no scientific information to determine if ac-
tivating substances should be used before PC injection.
Platelet activating substances are a necessary pre-
requisite for producing platelet gel from PC. Platelet gels
are used for covering large skin defects or for filling
bone defects either alone or combined with other bio-
materials. Platelet gels could be produced from PC acti-
vated with proteic and non-proteic substances or by
combination of both. Classically, bovine thrombin (ei-
ther alone or in combination with a calcium salt) has
been used for platelet gel production. Thrombin induces
fibrin polymerization by removing fibrinopeptides A and
B from the fibrin molecule. This protein also produces
platelet activation and massive release of growth factors.
Some clinicians prefer not to use bovine thrombin for
platelet gel formation because this substance induces cross-
reacting antibodies against coagulation factors V and XI [9].
Batroxobin induces fibrin polymerization by remov-
ing only the fibrinopeptide A. This substance does not
induce platelet activation or immunological reactions
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ommends the use of batroxobin plus calcium gluconate
for platelet gel formation. In the study presented here no
differences were noticed on the release of TGF-β1 from
both PC activated with CG or batroxobin plus CG.
Macroscopically no differences were noted about the
quality of the platelet gel formed or the time required
for clot formation. However, one limitation of this study
is that kinetics of gelation was not performed [9].
Results of this study corroborate that batroxobin in-
duce negligible platelet activation and the addition of
CG was necessary to induce the TGF-β1 release. This
phenomenon could be explained without the need of
using an experimental group of PC activated only with
batroxobin, since TGF-β1 concentration was statistically
similar for both PC, independently of the activating sub-
stance used, CG or batroxobin plus CG. This study is
limited since TGF-β1 release only was measured at once.
Further studies are necessary for knowing if the release
kinetics of this growth factor is time dependent or is
related to an activating substance in particular.
Collection and concentration efficiencies are two im-
portant aspects related with the capacity of and protocol
or device for concentrating the most possible number of
platelets and growth factors from a whole blood sample.
The protocol described here for producing PC and conse-
quently concentrating TGF-β1 was better than the cellular
and molecular results obtained for canine ACP protocol
[31] and the platelet concentration efficiency described for
a semi-automated method for producing canine PRP [23].
Conclusions
In summary, this study describes a simple and inexpen-
sive manual tube protocol for producing two PC with
different cellular and molecular characteristics. Release
of TGF-β1 from both PC at 2 h post-activation was
mainly dependent of CG. Further research is necessary
to determine the quality and strength of the platelet gel
formed before PC activation with CG or batroxobin (ei-
ther alone or in combination with CG). A study on the
kinetics of release of TGF-β1 and other platelet storage
growth factors from PC activated with several substances
during several hours should be performed.
Clinical studies are necessary to determine the actual
clinical utility of each PC produced with the protocol of
this study. Aspects related with the cellular or molecular
composition of PC possibly will determine the specific
use of each biodrug for a particular disease or tissue.
The use of platelet activating substance also will deter-
mine the specific clinical use of PC in dogs.
Methods
The ethics committee of animal research of Federal Uni-
versity of Minas Gerais approved this study.Animals
Sixteen male mongrel dogs were used, with age range
between 16 to 24 months and 15 Kg of average weight,
clinically healthy at time of blood collection and sero-
logically negative for leishmaniasis and ehrlichiosis.
Preparation of platelet concentrates
Blood collection was performed by puncturing the sa-
phenous vein with a butterfly catheter 21 G (Shandong
Weigao Group, Weihai, China). Blood was placed in
8.5 mL tubes with 1.5 mL of ACD-A (trisodium citrate
22 g/L, citric acid 8 g/L and dextrose 24.5 g/L) (Becton
Dickinson and Company, New Jersey, USA). Tubes were
centrifuged (SIGMA 3 K30, Osterode am Harz, Ger-
many) at 191 g for 6 minutes. Arbitrarily, the plasma
derived from blood centrifugation was divided in two
equal fractions, PC-A and PC-B. PC-A (lower PC frac-
tion) was considered as the first 50% of plasma next to
the packed cell volume (PCV) and PC-B (upper PC frac-
tion) was the 50% of remaining plasma in the tube.
Cellular evaluation
Blood samples and both PC were analyzed for hemo-
gram by using an automated counting device by volu-
metric impedance (Abacus Junior Vet, Budapest, Hungary).
Each sample was analyzed by triplicate. The hematol-
ogical parameters tested were hematocrit (PCV), platelet
count (PLT/μL), leukocyte count (WBC/μL), absolute
counts (cells/μL) and relative values (% cells) of lympho-
cytes (LYM), monocytes (MID), neutrophils, eosinophils
and basophils (GRA), mean platelet volume (MPV fL)
and platelet distribution width (PDW %).
Activation of platelet concentrates
Samples of one mL from PC-A and PC-B were divided
into aliquots of 500 μL and then activated with 50 μL of
CG 10% (Ropsohn Therapeutics Ltda, Bogotá, Colombia)
or batroxobin (Plateltex, Praha, Czech Republic) recon-
stituted with one mL of CG 10% (Ropsohn Therapeutics
Ltda, Bogotá, Colombia). After activated, the samples were
kept in incubation at room temperature (22°C) for two
hours [24]. Fibrin clots in each PC sample were released
from the tube walls and centrifuged at 1500 g for 10
minutes. Further, others plasma samples were obtained
by the centrifugation protocol described above. The
supernatants of activated PC and plasma samples were ali-
quoted and frozen at - 80°C for later determination of
TGF-β1 concentration.
Determination of total protein
Total protein (TP) concentration was measured by du-
plicate in both PC and plasma by using the biuret
method (Biosystems, Barcelona, Spain) in a semiauto-
matic chemistry analyser (RT-1904CV, Nanjing, China).
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tion of TGF-β1/TP released during PC activation.
Determination of the concentration of transforming
growth factor beta 1
Concentration of TGF-β1 (ng/mL) in plasma and both
PC were determined by ELISA sandwich, specifically
developed with antibodies against canine TGF-β1 (Mouse/
Rat/Porcine/Canine TGF-β1, MB100B, R&D Systems,
Minneapolis, USA). This protein had a mean detection
sensitivity of 4.6 pg/mL. ELISA was performed by dupli-
cate for each sample according to the manufacturer
instructions. Reading (Biochrom, Anthos 2010, Cam-
bridge, UK) was performed at 450 nm.
Statistically analysis
Data derived from this study presented normal distribu-
tion (Shapiro-Wilk test, P> 0.05) and analyzed variables
were presented as mean and mean standard error. Com-
parison between groups was performed using a one-way
ANOVA and post-hoc par-wise comparisons were per-
formed with a Student-Newman-Keuls (SNK) test. Cor-
relations between TGF-β1 concentrations and cellular
data were performed using a Pearson (ρ) test. A value of
P ≤ 0.01 was accepted as statistical significant for all
the tests.
Collection (concentration) efficiency
Platelet collection efficiency was determined by the for-
mula: (PC volume x platelet count in the PC/whole blood
volume x platelet count in whole blood) x 100 [33].
TGF-β1 concentration efficiency was determined by
the formula:(concentration of TGF-β1 in PC (ng/mL) x
volume of PC/plasmaTGF-β1 concentration (ng/mL) x
whole blood volume) x 100 [34].
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